Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: Stockholm
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Oasmia Pharmaceutical AB

+ Add to Watchlist

OASM:SS

20.1000 SEK 0.3000 1.52%

As of 11:29:59 ET on 01/30/2015.

Snapshot for Oasmia Pharmaceutical AB (OASM)

Open: 19.7000 Day's Range: 19.7000 - 20.2000 Volume: 44,726
Previous Close: 19.8000 52wk Range: 16.3425 - 31.0011 1-Yr Rtn: -14.01%

Stock Chart for OASM

No chart data available.
  • OASM:SS 20.1000
  • 1D
  • 1M
  • 1Y
19.8000
Interactive OASM Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for OASM

Current P/E Ratio (ttm) -
Estimated P/E(04/2015) -
Relative P/E vs. OMX -
Earnings Per Share (SEK) (ttm) -1.2678
Est. EPS (SEK) (04/2015) -
Est. PEG Ratio -
Market Cap (M SEK) 1,966.95
Shares Outstanding (M) 97.86
30 Day Average Volume 67,015
Price/Book (mrq) 6.1601
Price/Sale (ttm) 27,826.8109
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/05/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for OASM

  • Revenue
  • Net Income (M/SEK)
  • Profit Margin (%)

Company Profile & Key Executives for OASM

Oasmia Pharmaceutical AB is a pharmaceutical company that specializes in human and veterinary oncology. The Company's develops the semi-synthesized substances for different therapeutic areas, primarily for anti-cancer chemotherapy. Oasmia also conducts research within antibiotics, asthma and neurologically targeted drugs in clinical or preclinical stages.

Joel Tomas CitronChairmanJulian AleksovPresident/CEO/Co-Founder
Anders BlomExec Vice PresidentMargareta ErikssonVP:Clinical Development
More Company Profile & Key Executives for OASM

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil